RASSF5

Across TCGA pan-cancer cohorts, RASSF5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RASSF5 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RASSF5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RASSF5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where RASSF5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.841	0.586	.011	22	view →
PDAC	OS	Median	IV	0.395	0.937	.026	8	view →
LUAD	DFS	Quartile	II,III,IV	0.825	0.281	.032	6	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.457	.040	4	view →
GBM	OS	Quartile	All	0.337	0.617	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RASSF5–HNSC (OS)

Open the HNSC breakdown →